Cargando…

Immune-related adverse events induced by programmed death protein-1 inhibitors from the perspective of lymphoma immunotherapy

Lymphoma, which is highly malignant, stems from lymph nodes and lymphoid tissue. Lymphoma cells express programmed death-ligand 1/2 (PD-L1/PD-L2), which binds with programmed cell death 1 protein (PD-1) to establish inhibitory signaling that impedes the normal function of T cells and allows tumor ce...

Descripción completa

Detalles Bibliográficos
Autores principales: Hou, Yong-Zhe, Zhang, Qin, Bai, Hai, Wu, Tao, Chen, Ya-Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011990/
https://www.ncbi.nlm.nih.gov/pubmed/36926390
http://dx.doi.org/10.12998/wjcc.v11.i7.1458
_version_ 1784906523127840768
author Hou, Yong-Zhe
Zhang, Qin
Bai, Hai
Wu, Tao
Chen, Ya-Jie
author_facet Hou, Yong-Zhe
Zhang, Qin
Bai, Hai
Wu, Tao
Chen, Ya-Jie
author_sort Hou, Yong-Zhe
collection PubMed
description Lymphoma, which is highly malignant, stems from lymph nodes and lymphoid tissue. Lymphoma cells express programmed death-ligand 1/2 (PD-L1/PD-L2), which binds with programmed cell death 1 protein (PD-1) to establish inhibitory signaling that impedes the normal function of T cells and allows tumor cells to escape immune system surveillance. Recently, immune checkpoint inhibitor immunotherapies such as PD-1 inhibitors (nivolumab and pembrolizumab) have been introduced into the lymphoma treatment algorithm and have shown remarkable clinical efficacy and greatly improve prognosis in lymphoma patients. Accordingly, the number of lymphoma patients who are seeking treatment with PD-1 inhibitors is growing annually, which results in an increasing number of patients developing immune-related adverse events (irAEs). The occurrence of irAEs inevitably affects the benefits provided by immunotherapy, particularly when PD-1 inhibitors are applied. However, the mechanisms and characteristics of irAEs induced by PD-1 inhibitors in lymphoma need further investigation. This review article summarizes the latest research advances in irAEs during treatment of lymphoma with PD-1 inhibitors. A comprehensive understanding of irAEs incurred in immunotherapy can help to achieve better efficacy with PD-1 inhibitors in lymphoma.
format Online
Article
Text
id pubmed-10011990
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-100119902023-03-15 Immune-related adverse events induced by programmed death protein-1 inhibitors from the perspective of lymphoma immunotherapy Hou, Yong-Zhe Zhang, Qin Bai, Hai Wu, Tao Chen, Ya-Jie World J Clin Cases Minireviews Lymphoma, which is highly malignant, stems from lymph nodes and lymphoid tissue. Lymphoma cells express programmed death-ligand 1/2 (PD-L1/PD-L2), which binds with programmed cell death 1 protein (PD-1) to establish inhibitory signaling that impedes the normal function of T cells and allows tumor cells to escape immune system surveillance. Recently, immune checkpoint inhibitor immunotherapies such as PD-1 inhibitors (nivolumab and pembrolizumab) have been introduced into the lymphoma treatment algorithm and have shown remarkable clinical efficacy and greatly improve prognosis in lymphoma patients. Accordingly, the number of lymphoma patients who are seeking treatment with PD-1 inhibitors is growing annually, which results in an increasing number of patients developing immune-related adverse events (irAEs). The occurrence of irAEs inevitably affects the benefits provided by immunotherapy, particularly when PD-1 inhibitors are applied. However, the mechanisms and characteristics of irAEs induced by PD-1 inhibitors in lymphoma need further investigation. This review article summarizes the latest research advances in irAEs during treatment of lymphoma with PD-1 inhibitors. A comprehensive understanding of irAEs incurred in immunotherapy can help to achieve better efficacy with PD-1 inhibitors in lymphoma. Baishideng Publishing Group Inc 2023-03-06 2023-03-06 /pmc/articles/PMC10011990/ /pubmed/36926390 http://dx.doi.org/10.12998/wjcc.v11.i7.1458 Text en ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Minireviews
Hou, Yong-Zhe
Zhang, Qin
Bai, Hai
Wu, Tao
Chen, Ya-Jie
Immune-related adverse events induced by programmed death protein-1 inhibitors from the perspective of lymphoma immunotherapy
title Immune-related adverse events induced by programmed death protein-1 inhibitors from the perspective of lymphoma immunotherapy
title_full Immune-related adverse events induced by programmed death protein-1 inhibitors from the perspective of lymphoma immunotherapy
title_fullStr Immune-related adverse events induced by programmed death protein-1 inhibitors from the perspective of lymphoma immunotherapy
title_full_unstemmed Immune-related adverse events induced by programmed death protein-1 inhibitors from the perspective of lymphoma immunotherapy
title_short Immune-related adverse events induced by programmed death protein-1 inhibitors from the perspective of lymphoma immunotherapy
title_sort immune-related adverse events induced by programmed death protein-1 inhibitors from the perspective of lymphoma immunotherapy
topic Minireviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011990/
https://www.ncbi.nlm.nih.gov/pubmed/36926390
http://dx.doi.org/10.12998/wjcc.v11.i7.1458
work_keys_str_mv AT houyongzhe immunerelatedadverseeventsinducedbyprogrammeddeathprotein1inhibitorsfromtheperspectiveoflymphomaimmunotherapy
AT zhangqin immunerelatedadverseeventsinducedbyprogrammeddeathprotein1inhibitorsfromtheperspectiveoflymphomaimmunotherapy
AT baihai immunerelatedadverseeventsinducedbyprogrammeddeathprotein1inhibitorsfromtheperspectiveoflymphomaimmunotherapy
AT wutao immunerelatedadverseeventsinducedbyprogrammeddeathprotein1inhibitorsfromtheperspectiveoflymphomaimmunotherapy
AT chenyajie immunerelatedadverseeventsinducedbyprogrammeddeathprotein1inhibitorsfromtheperspectiveoflymphomaimmunotherapy